JP2016509062A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509062A5
JP2016509062A5 JP2015558996A JP2015558996A JP2016509062A5 JP 2016509062 A5 JP2016509062 A5 JP 2016509062A5 JP 2015558996 A JP2015558996 A JP 2015558996A JP 2015558996 A JP2015558996 A JP 2015558996A JP 2016509062 A5 JP2016509062 A5 JP 2016509062A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
cycloalkyl
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509062A (ja
JP6186012B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/017688 external-priority patent/WO2014130810A1/en
Publication of JP2016509062A publication Critical patent/JP2016509062A/ja
Publication of JP2016509062A5 publication Critical patent/JP2016509062A5/ja
Application granted granted Critical
Publication of JP6186012B2 publication Critical patent/JP6186012B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558996A 2013-02-25 2014-02-21 C−3アルキルおよびアルケニル修飾ベツリン酸誘導体 Expired - Fee Related JP6186012B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768630P 2013-02-25 2013-02-25
US61/768,630 2013-02-25
PCT/US2014/017688 WO2014130810A1 (en) 2013-02-25 2014-02-21 C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv

Publications (3)

Publication Number Publication Date
JP2016509062A JP2016509062A (ja) 2016-03-24
JP2016509062A5 true JP2016509062A5 (enExample) 2016-12-15
JP6186012B2 JP6186012B2 (ja) 2017-08-23

Family

ID=50288267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558996A Expired - Fee Related JP6186012B2 (ja) 2013-02-25 2014-02-21 C−3アルキルおよびアルケニル修飾ベツリン酸誘導体

Country Status (15)

Country Link
US (1) US9249180B2 (enExample)
EP (1) EP2958930A1 (enExample)
JP (1) JP6186012B2 (enExample)
KR (1) KR20150121712A (enExample)
CN (1) CN105102468A (enExample)
AR (1) AR094876A1 (enExample)
AU (1) AU2014218754B2 (enExample)
BR (1) BR112015019590A2 (enExample)
CA (1) CA2902513A1 (enExample)
EA (1) EA027861B1 (enExample)
IL (1) IL240739A0 (enExample)
MX (1) MX2015010354A (enExample)
SG (1) SG11201506445PA (enExample)
TW (1) TW201444862A (enExample)
WO (1) WO2014130810A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
WO2016168447A1 (en) * 2015-04-14 2016-10-20 VIIV HEALTHCARE (No.4) LIMITED Methods of producing an hiv maturation inhibitor
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018044838A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2019055119A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION
CN106749486A (zh) * 2016-11-30 2017-05-31 沈阳化工大学 一种以乙二胺为连接臂的齐墩果酸衍生物及其应用
MX2020002884A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
BR112020020273A2 (pt) 2018-04-03 2021-04-06 Blueprint Medicines Corporation Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret
US12275712B2 (en) 2019-02-11 2025-04-15 Hetero Labs Limited Triterpene derivatives as HIV inhibitors
CN111362923A (zh) * 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
CN111440151A (zh) * 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
RU2020130238A (ru) 2020-03-31 2022-03-14 Феникс Байотекнолоджи, Инк. Способ и композиции для лечения коронавирусной инфекции
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
EP4157829A1 (en) 2020-05-29 2023-04-05 Blueprint Medicines Corporation Solid forms of pralsetinib

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
ES2548905T3 (es) 2010-06-04 2015-10-21 Bristol-Myers Squibb Company Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
EP2576585B8 (en) 2010-06-04 2016-12-21 VIIV Healthcare UK (No.5) Limited Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
SI2670764T1 (sl) 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
CA2826113C (en) 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Similar Documents

Publication Publication Date Title
JP2016509062A5 (enExample)
JP2016507558A5 (enExample)
JP2015510515A5 (enExample)
JP2014507422A5 (enExample)
JP2013527242A5 (enExample)
UY38297A (es) Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos
TN2018000048A1 (en) Antiviral beta-amino acid ester phosphodiamide compounds
JP2013527243A5 (enExample)
NZ729150A (en) Antiretroviral agents
HRP20151212T1 (hr) C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
JOP20190115A1 (ar) مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp)
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
JP2014526554A5 (enExample)
UY35263A (es) Compuestos terapéuticos
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
NZ721534A (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
JP2018521020A5 (enExample)
MX373713B (es) Compuestos pirazolopirimidina.
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
MX392270B (es) Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
HRP20210502T1 (hr) Triterpenoidi modificirani na c-3 i c-17 kao inhibitori hiv-1